An overview on inactivated and live‐attenuated SARS‐CoV‐2 vaccines
S Khoshnood, M Arshadi, S Akrami… - Journal of Clinical …, 2022 - Wiley Online Library
After about 2 years since severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2),
first infections were detected in Wuhan city of China in December 2019, which was followed …
first infections were detected in Wuhan city of China in December 2019, which was followed …
Variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and vaccine effectiveness
SRV Tulimilli, S Dallavalasa, CG Basavaraju… - Vaccines, 2022 - mdpi.com
The incidence and death toll due to SARS-CoV-2 infection varied time-to-time; and
depended on several factors, including severity (viral load), immune status, age, gender …
depended on several factors, including severity (viral load), immune status, age, gender …
Safety and Immunogenicity of Inactivated Whole Virion COVID-19 Vaccine CoviVac in Clinical Trials in 18–60 and 60+ Age Cohorts
IV Gordeychuk, LI Kozlovskaya, AA Siniugina… - Viruses, 2023 - mdpi.com
We present the results of a randomized, double-blind, placebo-controlled, multi-center
clinical trial phase I/II of the tolerability, safety, and immunogenicity of the inactivated whole …
clinical trial phase I/II of the tolerability, safety, and immunogenicity of the inactivated whole …
The fast-track development of COVID-19 vaccines
Despite the importance of the preventive vaccines sector against communicable diseases, it
did not take sufficient attention to it in terms of funding in recent years, but the emergence …
did not take sufficient attention to it in terms of funding in recent years, but the emergence …